Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies
Frontiers in Pharmacology, 2017 We evaluated the prevalence of and risk factors for hypersensitivity reactions related to carboplatin, which is commonly used to treat gynecological malignancies.
Yu-Hsiao Tai +15 more
doaj +1 more source
IJU Case Reports, 2023 Introduction Small‐cell carcinoma of the urinary bladder has a poor prognosis, and no standard treatment has been established. We encountered a case of a patient with metastasis in which complete response and long‐term survival were obtained by treating ...
Shinya Miyazaki +4 more
doaj +1 more source
Carboplatin hypersensitivity in relapsed ovarian carcinoma: A therapeutic challenge
Indian Journal of Medical and Paediatric Oncology, 2014 Carboplatin and paclitaxel as doublet are the standard therapeutic option for advanced stage ovarian carcinoma in the first line as well as relapse. Carboplatin with its better toxicity profile has replaced cisplatin as the first line drug.
Avinash Pandey +6 more
doaj +1 more source
In Vitro MCF-7 Cells Apoptosis Analysis of Carboplatin Loaded Silk Fibroin Particles
Molecules, 2020 Breast cancer ranks as the fifth leading cause of death worldwide. Chemotherapy is commonly used directly or as neo-adjuvant therapy for the management of breast cancer with its attendant adverse effects, underscoring the need to develop biocompatible ...
Nanyak Galam, Pinar Tulay, Terin Adali
doaj +1 more source
PARP inhibition: a promising therapeutic target in ovarian cancer [PDF]
, 2015 Ovarian cancer is burdened by the highest mortality rate among gynecological cancers. Gold standard is represented by the association of platinum-taxane -based chemotherapy and radical surgery.
Abdul Halim, T +14 more
core +1 more source
Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization. [PDF]
, 2016 RRx-001, an experimental systemically non-toxic epi-immunotherapeutic agent, which potentiates the resensitization of resistant cancer cells to formerly effective therapies, is under active investigation in several clinical trials that are based on ...
Brzezniak, Christina +8 more
core +7 more sources
Case Reports in Oncology, 2020 A standard chemotherapy regimen for advanced thymic carcinoma has not yet been established. We treated 2 cases of thymic carcinoma with carboplatin plus nanoparticle albumin-bound (nab)-paclitaxel, and nab-paclitaxel maintenance therapy.
Tomoyuki Araya +5 more
doaj +1 more source
A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss
Frontiers in Oncology, 2021 The treatment landscape of metastatic castration-resistant prostate cancer (mCRPC) has dramatically improved over the last decade; however, patients with visceral metastases are still faced with poor outcomes.
Zin W. Myint +6 more
doaj +1 more source
Fanconi anemia pathway regulation by FANCI in prostate cancer
Frontiers in Oncology, 2023 Prostate cancer is one of the leading causes of death among men worldwide, and thus, research on the genetic factors enabling the formation of treatment-resistant cancer cells is crucial for improving patient outcomes.
Heidi Kaljunen +7 more
doaj +1 more source
Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study. [PDF]
, 2017 Background Circulating tumor cells (CTCs) and chemokine (C-X-C motif) receptor 4 (CXCR4) expression in CTCs and tumor tissue were evaluated as prognostic or predictive markers of CXCR4 peptide antagonist LY2510924 plus carboplatin-etoposide (CE) versus ...
Baeten, Kurt +19 more
core +1 more source